drugset / Trial / NCT06791772

Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE)

NCT06791772

Phase 2 Not yet recruiting 150 enrolled Keymed Biosciences Co.Ltd
RandomizedParallel-groupTriple-blindTreatment

Summary

To evaluate the efficacy and safety of CM313(SC) injection in systemic lupus erythematosus(SLE)

Timeline

Start
2025-02
Primary completion
2026-10
Completion
2027-02

Drugs

EvaluationDrugModalityDoseRoute
Subject LUMROTATUG Monoclonal antibody 600 mg Subcutaneous
Subject LUMROTATUG Monoclonal antibody 1200 mg Subcutaneous